Acta Med. 2014, 57: 49-55
https://doi.org/10.14712/18059694.2014.39
RADIOIODINE TREATMENT OF GRAVES’ DISEASE – DOSE/RESPONSE ANALYSIS
References
1. Lancet 2012; 379(9821): 1155–66.
< JA, Boelaert K. Thyrotoxicosis. https://doi.org/10.1016/S0140-6736(11)60782-4>
2. Ther Clin Risk Manag 2010; 6: 29–40.
P, Acharya S. Current and emerging treatment options for Graves’ hyperthyroidism.
3. N Engl J Med 2011; 364(6): 542–50.
< DS. Radioiodine therapy for hyperthyroidism. https://doi.org/10.1056/NEJMct1007101>
4. Thyroid 1991; 1(2): 129–35.
< L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. https://doi.org/10.1089/thy.1991.1.129>
5. J Clin Endocrinol Metab 2012; 97(12): 4549–58.
< HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. https://doi.org/10.1210/jc.2012-2802>
6. Clin Endocrinol (Oxf) 2004; 61(5): 641–8.
< S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. https://doi.org/10.1111/j.1365-2265.2004.02152.x>
7. N Engl J Med 1984; 311(7): 426–32.
< V, Mccormick M, Kaplan EL, Fauchet R, Degroot LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves’ disease. https://doi.org/10.1056/NEJM198408163110702>
8. Thyroid 2011; 21(6): 593–646.
RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.
9. Clin Endocrinol (Oxf) 2007; 66(6): 757–64.
< AP. Radioiodine treatment for benign thyroid diseases. https://doi.org/10.1111/j.1365-2265.2007.02841.x>
10. Ulster Med J 2013; 82(2): 85–8.
A, Atkinson B, Bell P, et al. Outcome of 131I therapy in hyperthyroidism using a 550 MBq fixed dose regimen.
11. Intern Med J 2010; 40(12): 854–7.
< SK, Mcgrath S, Rogers K, et al. Fixed dose (555 MBq; 15 mCi) radioiodine for the treatment of hyperthyroidism: outcome and its predictors. https://doi.org/10.1111/j.1445-5994.2010.02348.x>
12. Clin Endocrinol (Oxf) 1988; 28(5): 487–96.
< AB, Brownlie BE, Frampton CM, Turner JG, Rogers TG. Outcome following standardized 185 MBq dose 131I therapy for Graves’ disease. https://doi.org/10.1111/j.1365-2265.1988.tb03683.x>
13. Clin Endocrinol (Oxf) 1991; 35(3): 207–12.
< JJ, Toft AD. Iodine-131 treatment of hyperthyroidism: current issues. https://doi.org/10.1111/j.1365-2265.1991.tb03523.x>
14. Eur J Nucl Med 2001; 28(10): 1489–95.
< D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves’ disease: a clinical outcome study. https://doi.org/10.1007/s002590100621>
15. Clin Endocrinol (Oxf) 1995; 43(3): 325–9.
< AE, Hegedus L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? https://doi.org/10.1111/j.1365-2265.1995.tb02039.x>
16. Eur J Clin Invest 1995; 25(3): 186–93.
< H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. https://doi.org/10.1111/j.1365-2362.1995.tb01547.x>
17. J Clin Endocrinol Metab 2003; 88(3): 978–83.
< WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. https://doi.org/10.1210/jc.2002-020805>
18. Eur J Nucl Med 1985; 11(6–7): 191–3.
< J, Sadler W, Brownlie B, Rogers T. Radioiodine therapy for Graves’ disease: multivariate analysis of pretreatment parameters and early outcome. https://doi.org/10.1007/BF00279066>
19. Thyroid 2011; 21(6): 585–91.
< GJ, Bartalena L, Hegedus L. The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. https://doi.org/10.1089/thy.2011.2106.ed3>
20. Thyroid 2012; 22(10): 991–5.
< S, Nakatani VY, Bortolini LG, Boguszewski CL, Graf H, De Carvalho GA. Evidence for higher success rates and successful treatment earlier in Graves’ disease with higher radioactive iodine doses. https://doi.org/10.1089/thy.2011.0362>
21. J Clin Endocrinol Metab 2001; 86(8): 3611–7.
A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
22. J Clin Endocrinol Metab 2003; 88(3): 975–7.
< JE, Mcdougall IR. How should the dose of iodine-131 be determined in the treatment of Graves’ hyperthyroidism? https://doi.org/10.1210/jc.2002-021801>
23. J Clin Endocrinol Metab 1998; 83(2): 685–7.
< RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. https://doi.org/10.1210/jcem.83.2.4538>
24. J Clin Endocrinol Metab 1996; 81(9): 3257–60.
Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N. Changes in thyroid volume in response to radioactive iodine for Graves’ hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome.
25. Clin Endocrinol (Oxf) 2009; 70(1): 129–38.
< K, Syed AA, Manji N, et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. https://doi.org/10.1111/j.1365-2265.2008.03291.x>
26. Endocrine 2004; 25(1): 55–60.
< C, Kandemir N, Hacihasanoglu A, Ersoz HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. https://doi.org/10.1385/ENDO:25:1:55>
27. J Clin Endocrinol Metab 2001; 86(8): 3488–93.
VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study.
28. J Clin Endocrinol Metab 2000; 85(3): 1038–42.
A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves’ hyperthyroidism.
29. J Clin Endocrinol Metab 1999; 84(4): 1229–33.
O, Zimny M, Schulz G, et al. Success rate of radioiodine therapy in Graves’ disease: the influence of thyrostatic medication.
30. Hormones (Athens) 2009; 8(4): 273–8.
< A, Ghosh S, Hair M, Malik I, Mcgarvie J. Comparison of two fixed activities of radioiodine therapy (370 vs. 555 MBq) in patients with Graves’ disease. https://doi.org/10.14310/horm.2002.1243>
31. BMJ 2007; 334(7592): 514.
< MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. https://doi.org/10.1136/bmj.39114.670150.BE>
<PubMed>
32. Thyroid 2004; 14(7): 525–30.
< RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. https://doi.org/10.1089/1050725041517093>
33. J Clin Endocrinol Metab 2004; 89(9): 4439–44.
< SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L. Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. https://doi.org/10.1210/jc.2004-0247>
34. Thyroid 2002; 12(2): 135–9.
< M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial. https://doi.org/10.1089/105072502753522365>
35. N Engl J Med 1994; 330(24): 1731–8.
JA. The management of hyperthyroidism.
36. J Clin Endocrinol Metab 2002; 87(3): 1073–7.
EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease.
37. J Clin Endocrinol Metab 1998; 83(1): 40–6.
L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves’ patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
38. J Clin Endocrinol Metab 1999; 84(2): 499–503.
F, Bartalena L, Brogioni S, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves’ hyperthyroidism.
39. Cancer Biother Radiopharm 2005; 20(2): 218–23.
< M, Traino A, Boni G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves’ hyperthyroidism. https://doi.org/10.1089/cbr.2005.20.218>
40. J Clin Endocrinol Metab 2003; 88(12): 6113.
< J, Franklyn JA. Radioiodine treatment of Graves’ hyperthyroidism. https://doi.org/10.1210/jc.2003-031172>